

VAICEKAUSKAITE Indre (TRADE)

Subject: FW: Meeting Lilly 4 March

From: FEZAS VITAL Isabel (TRADE)

Sent: Friday, March 08, 2013 5:03 PM

To: HANNONEN Marjut (CAB-DE GUCHT); EMBERGER Geraldine (TRADE); SORENSEN Carsten (TRADE); MARGHERITA Michelangelo (TRADE); BENGTSSON Claes (CAB-DE GUCHT)

Cc: LEVIE Damien (TRADE); SOURMELIS Petros (TRADE); PERREAU DE PINNINCK Fernando (TRADE); GARCIA BERCERO Ignacio (TRADE); RATSO Signe (TRADE)

Subject: Meeting Lilly 4 March

Meeting with CEO of Eli Lilly and Company - 4 March 2013

Participants:

Marjut Hannonen (CAB-DE GUCHT), Isabel Fezas Vital (DG TRADE/G3)

Dr John Lechleiter (CEO of Lilly), [Art. 4.1(b)] Lilly's Brussels office, [Art. 4.1(b)] at Fleishman-Hillard

Report:

[not relevant]

As regards the EU-US Trade and Investment Agreement, Lilly (J. Lechleiter) expressed strong support to the negotiation, which should be comprehensive and ambitious, addressing regulatory harmonization, intellectual property, market provisions, customs, tariffs and public procurement measures. He hopes that the negotiations will set ambitious goals on regulatory harmonization aspects, including mutual recognition and clinical trials, and also that they will establish principles on pricing and reimbursement, as it happened in the EU-Korea FTA. He highlighted the joint reply from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) to the request for Public Comments on Promoting US EC Regulatory Compatibility, which he handed over.

[not relevant]

COM noted that the negotiations with the US will be very challenging. It is expected that the agreement with the US will be important also for trade relations with other partners. The focus of the negotiations will be on regulatory issues. The negotiations on regulatory convergence will be tough.